Evommune, Inc. (EVMN)
13.23
-0.25
(-1.85%)
USD |
NYSE |
Aug 28, 16:00
13.22
-0.01
(-0.08%)
After-Hours: 20:00
Evommune Cash from Operations (Quarterly) : -20.32M for June 30, 2026
Cash from Operations (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Cash from Operations (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -20.32M |
| March 31, 2026 | -27.50M |
| December 31, 2025 | -16.70M |
| September 30, 2025 | -9.635M |
| June 30, 2025 | -26.21M |
| Date | Value |
|---|---|
| March 31, 2025 | -23.90M |
| September 30, 2024 | -26.23M |
| June 30, 2024 | -8.626M |
| March 31, 2024 | -4.83M |
Cash From Operations Definition
Represents the net cash flow from the company's business operations.
Cash from Operations (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Operations (Quarterly) Benchmarks
| MapLight Therapeutics, Inc. | -44.87M |
| Mineralys Therapeutics, Inc. | -32.56M |
| Arrowhead Pharmaceuticals, Inc. | -177.47M |
| Oncolytics Biotech, Inc. | -8.066M |
| Sangamo Therapeutics, Inc. | -19.28M |
Cash from Operations (Quarterly) Related Metrics
| Cash from Investing (Quarterly) | 31.29M |
| Cash from Financing (Quarterly) | 0.532M |
| Free Cash Flow | -74.65M |
| Free Cash Flow Per Share (Quarterly) | -0.5673 |
| Free Cash Flow to Equity (Quarterly) | -20.01M |
| Free Cash Flow to Firm (Quarterly) | -20.50M |
| Free Cash Flow Yield | -16.99% |